EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Factors influencing nonleukemic death in refractory anemia, refractory anemia with ring sideroblasts, and refractory anemia with excess of blasts



Factors influencing nonleukemic death in refractory anemia, refractory anemia with ring sideroblasts, and refractory anemia with excess of blasts



Cancer Research 47(13): 3599-3602



The association between nonleukemic death and various features recorded at presentation in patients with refractory anemia (RA), RA with ring sideroblasts, and RA with excess of blasts was analyzed in 251 patients using the proportional hazards model. Features associated with higher nonleukemic death rates were: 1% or more metamyelocytes in peripheral blood (PB); lower 59Fe incorporation rate; 1% or more blasts in PB; lower hematocrit or hemoglobin; presence of giant platelets; 1 microgram/liter or higher serum vitamin B12 levels; higher periodic acid-Schiff positive erythroblasts; and 1% or higher promyelocytes in PB. Multivariate analysis was also performed using the following predictor variables: metamyelocytes in PB, micromegakaryocytes, hemoglobin, giant platelets, presence or absence of RA with excess of blasts, and mononuclear large megakaryocytes. Patients were divided arbitrarily into low (hazard ratio, less than 0.55), intermediate (hazard ratio, 0.55-1.5), and high (hazard ratio, greater than 1.5) risk groups. The cumulative nonleukemic death rates in the high and intermediate risk groups reached a median at 602 and 1984 days from presentation, respectively, while the rate reached a plateau level of 49.4% after 2644 days in the low risk group. The risk factors for leukemic transformation and nonleukemic death were found to be different and to need separate consideration.

(PDF emailed within 1 workday: $29.90)

Accession: 005441946

Download citation: RISBibTeXText

PMID: 3581090



Related references

Development of refractory anemia with ring sideroblasts associated with thrombocytosis from pre-existing refractory anemia with ring sideroblasts through acquisition of Jak2 V617F mutation. Leukemia & Lymphoma 52(12): 2405-2407, 2012

Comparison of idarubicin+ara-C-, fludarabine+ara-C-, and topotecan+ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 98(13): 3575-3583, December 15, 2001

Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia (AML)) on outcome of AML-type chemotherapy. Blood 90(8): 2969-2977, 1997

Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90(8): 2969-2977, 1997

Susceptibility to Infection Due to Diminished Interferon-α-Producing Capacity in Patients with Refractory Anemia with Excess of Blasts or Refractory Anemia with Excess of Blasts in Transformation. Hematology 2(2): 131-138, 1997

Re-analysis of prognosis in refractory anemia alone, with ring sideroblasts, and with excess of blasts. International Journal of Hematology 57(1): 15-25, 1993

A Randomized Trial of Interferon Alfa and Granulocyte Macrophage Colony Stimulating Factor Versus IFN and Cytarabine Versus Idarubicin and Ara-C for Maintenance Therapy in Acute Myelogenous Leukemia , Refractory Anemia with Excess of Blasts , Refractory Anemia with Excess of Blasts in Transformation in First Complete Remission. Blood 100(11): Abstract No 4571, November 16, 2002

Myelodysplastic syndromes: prognostic significance of multilineage dysplasia in patients with refractory anemia or refractory anemia with ringed sideroblasts. Blood 99(10): 3870-1; Author Reply 3871, 2002

Improved identification of refractory anemia and refractory anemia with ringed sideroblasts using red cell volume distribution width. American Journal of Clinical Pathology 101(3): 391, 1994

Prognostic value of multilineage dysplasia and bone marrow histology in the FAB subgroups of refractory anemia and refractory anemia with ringed sideroblasts and possible relevance in the new WHO proposal. Leukemia Research 27(Supplement 1): S19-S20, 2003

Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors. Medicina Clinica 142(2): 91-92, 2014

Prognostic significance of some clinical morphological and cytogenetic findings in refractory anemia and refractory anemia with sideroblasts. Blut 52(1): 35-44, 1986

Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome. Proteome Science 11(1): 14-14, 2013

Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile. Leukemia Research 31(10): 1373-1382, 2006

Refractory anemia with ring sideroblasts masked by iron deficiency anemia. Blood 117(22): 5793-5793, 2011